Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients with Parathyroid Carcinoma or Primary Hyperparathyroidism who are Unable to Undergo Parathyroidectomy or Relapse after Parathyroidectomy

Next Previous
Trial Profile

An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients with Parathyroid Carcinoma or Primary Hyperparathyroidism who are Unable to Undergo Parathyroidectomy or Relapse after Parathyroidectomy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evocalcet (Primary)
  • Indications Hypercalcaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin; Kyowa Kirin

Most Recent Events

  • 01 Sep 2020 Results published in the Journal of Bone and Mineral Metabolism
  • 14 Jun 2019 Status changed from active, no longer recruiting to completed.
  • 24 Apr 2019 Results published in the Kyowa Hakko Kirin media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top